\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\usepackage{float}

\begin{document}


\def\RunningAuthor{Gowda D V , et al.}
\firstPage{1377}
\articleType{Review Article}
\receivedDate{15.08.2019}
\acceptedDate{25.11.2019}
\revisedDate{17.11.2019}
\journalVolume{2020, 11}
\journalIssue{2}
\journalDoi{ijrps.v11i2.2003}
\copyrightYear{2020}
\def\authorCount{3}
\def\affCount{1}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{A comprehensive review on application of stem cells for kidney diseases}
\author{Chetan~Kumar~V~H,  
            Famna~Roohi~N~K, 
            Gowda~D~V\textsuperscript{*}~\\[5pt]{Department of Pharmaceutics\unskip, JSS College of Pharmacy, JSS Academy of Higher Education and Research                                 , Mysuru, karnataka, India}}

\begin{abstract}
The recognition of kidney failure as a complex disease requires multi-factorial therapy in order to correct the conventional non-factorial deficiency. Firstly, self-renewal means the ability of most organisms to reproduce without separation or aging; secondly, more than one form of a mature somatic cell is identified by each of the three regardless of kidney disorders, it can lead to loss of the environment, often bacterial infections. The reconstruction of the kidney has produced a spectacular response in this framework. The restoration of weakened and new kidneys is an alternative to renal replacement therapy. Both teratomas and embryoid bodies consist of three different layers of embryonic germs. Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are present. These either provide useful therapeutical resources or can explore pathophysiology, including kidney diseases or infection. The benefit of ESCs is that they are relatively quick to receive and no longer subject to licensing/realty fees. Nevertheless,  there are still some major concerns, such as ethical issues, the high risks to degeneration of neoplasm and immuno compatibility. The great benefit of iPSCs is that they have the same genetic history they drive making them an excellent method for studying the impact of genetic variants on disease path the key risk associated with the use of iPSCs are oogenesis, Tumorigenicity, and immunogenicity, the presence of an epigenetic memory, technical and economic issue associated with their long turnaround time and the presence of loyalties are the key risks associated with the use of iPSCs. Human pluripotent SCs have two major areas of use in kidney regeneration: they can be used by way organoid, scaffold, organ-on-a-chip, or blastocyst experiment to develop a "new kidney" or part of it. For encouraging us to hypothesize their medical use, a deeper understanding of the biology of pluripotent SCs is necessary.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Pluripotency,\newline Renal replacement therapy,\newline teratomas,\newline Human pluripotent SC
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Gowda~D~V~\\ Phone:\ ~\\  Email:\ dvgowda@jssuni.edu.in
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Acute and chronic kidney failure is a condition with a high rate of diseases and is a major issue worldwide. The study survey shows that more than 10\% suffer from a major level of chronic kidney disease (CKD)\unskip~\citep{649098:15251420}. Regardless of kidney conditions, this can contribute to loss of renal function system, often contributing to infection with bacteria. In the end stage of renal diseases, CKD can be improved, requiring kidney transplantation and dialysis to allow patients to survive.  Never the less affordable the healthcare and economic problem to survive long term renal replacement therapy (RRT) \unskip~\citep{649098:15251395} this is why the reconstruction of the kidney is in higher demand. Building a new kidney and rebuilding a new kidney is an emergency substitute for renal replacement therapy (RRT). In this sense, kidney regeneration was remarkable was a remarkable response. The alternative to renal replacement therapy is the regeneration of damaged or new kidneys. Adult kidney disease has a very low number of nephrons identified from embryonic development, as kidney regeneration provides few adverse opportunities for nephrology medicine in humans. 

\textbf{Pluripotent SCs}

Cells are cultured from blastocyst; the embryo is capable of generating a whole body \unskip~\citep{649098:15251397}. We have two primary properties from a technical point of view. A great differentiation and proliferative capacity. Each of the three embryonic layers of germs developed from more than one mature somatic cell in the differentiation property (ectoderm, mesoderm, and endoderm) and second consisted of self-renewal, which has the ability to replicate to expand extensively without undergoing differentiation\unskip~\citep{649098:15251405}. Pluripotent SCs mammals, which include human during the embryonic development exhaust progressively this can affect insufficient stem cell/progenitor cells. The population and the capacity to rebuild the organs by constructing and maintaining the function of stem cells depend on the ability to withstand fetal life in the cellular function. Based on their versatility, long term, \textit{in vitro,} pluripotent SCs can be grown. When they are exposed to culture condition (e.g., pluripotency that is obtained by growth factor) pluripotent SCs that undergo differentiation, when transporting \textit{in vitro } pluripotent SCs, differentiation evolves into embryonic bodies implantation into the host cell of an immunodeficient animal by way of which these cells are teratomas \unskip~\citep{649098:15251422}. All embryoid and tetratomic bodies comprise three distinct layers of embryonic germ layers, which from the pluripotent origin. To acquire a mature renal cell, pluripotent SCs undergo direct differentiation, which has been demonstrated exclusively for embryonic development\unskip~\citep{649098:15251400}.

\textbf{Human Pluripotent stem cell}

Regardless of its type, cultivated cells derived from pluripotent SCs that are part of the blastocyst stage embryos are capable of making the entire body \unskip~\citep{649098:15251397}. They have two main features from a practical point of view: high dispersibility and the possibility of wide differentiation capabilities. The first also referred to as self-renewal, refers to the ability to replicate most without separation or aging, while the second refers to the ability to distinguish between more than one type of mature somatic cell and each of the three embryos\unskip~\citep{649098:15251410}. Pluripotent SC decreases progressively in mammals including humans, during the course of embryonic developments, which may cause tissue-linked stem cells/progeny, often referred to as special stem cells/progeny functional features of the cell population, together with the potential for regenerating the organ they are in enable the stem cells to develop and maintain their function, are crucial to preserving their ability to live on after fetal life. Due to the way it functions, SC pluripotent can be cultivated \textit{in vitro} in the long term, when pluripotent SC is subject to certain environmental factors (For instance, lack of pluripotency growth factors), they are stochastically differentiated. Therefore, they start embryoid bodies \textit{in vitro}, while these cells produce teratomas through implantation in hosts of immunodeficient animals \unskip~\citep{649098:15251400}. Due to the three layers of embryonic germ, both the embryoid body and teratoma comprise cell types, thereby showing a plurality of cells where they derive from. Moreover, direct differentiation through exposure to SC, which is pluripotent to growth or inhibiting factors that specifically control the progressive developmental stages, is an alternative choice for attracting the interest of adult cells, particularly kidney cells\unskip~\citep{649098:15251390}.

Human pluripotent SC which is given in the Figure~\ref{f-17523ff082a6} consists of embryonic stem cells (ESC) and induced pluripotent stem cell (iPSC). However, the features of these two cell types are demonstrated as pluripotent SCs. The cells are useful tools to research pathophysiology and the mechanism of disease, or for therapeutic purposes.


\bgroup
\fixFloatSize{images/1f9674b8-efd0-452a-b50a-312810c62040-upicture1.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/1f9674b8-efd0-452a-b50a-312810c62040-upicture1.png}{\includegraphics{images/1f9674b8-efd0-452a-b50a-312810c62040-upicture1.png}}{}
\makeatother 
\caption{\boldmath {The potential use of human pluripotent stem cells to kidney regeneration}}
\label{f-17523ff082a6}
\end{figure}
\egroup
\textbf{Embryonic stem cell}

Embryonic stem cells are the main human embryo cell culture around 5 after fertilization and are isolated and subsequently cultivated from embryos \unskip~\citep{649098:15251422} and divided into different cell types in culture. The embryo cells are grown in culture after they emerge from embryos. They help in providing positive results for kidney regeneration therapies Figures~\ref{f-17523ff082a6} and~\ref{f-def9d660b7b2} ESC has the ability to differentiate in different mature kidney cells. Some studies were done on mouse ESC were differentiated into renal tubular cells in nephrons \unskip~\citep{649098:15251417}. Few types of research show ES cells that might distinguish in the embryonic kidney micro-environment into kidney structures. \ensuremath{\beta }-galactosidase expressed in the embryonic kidney after ES cell injection, ES cells that express \ensuremath{\beta }-galactosidase have been shown to form tubules and tough glomerular epithelia \unskip~\citep{649098:15251419}. Within 20 weeks, ESCs can be obtained. Yet ES cell work has made little progress on account of the ethical problem.

\textbf{Induced pluripotent stem cells}

Excess embryonic transcription factors were induced in temporary somatic cells (OCT4, KLF4, c-MYC SOX2, in the first study), which caused cells to enter phenotypic, functional, and functional ESC conditions. iPSCs are less likely to continue after reprogramming by vector integration methods (e.g., Sendai viruses, plasmids, RNA synthesized, proteins) \unskip~\citep{649098:15251389}. IPSCs na{\"{\i}}ve models of an internal blastocyst cell mass before implantation, whereas the iPSC prime closely resembles the cells from the epiblasts after implementation. The iPSC can be considered primitive and na{\"{\i}}ve.

Naive iPSCs are usually easier to maintain and distinguish but must be collected under chemical conditions. The variations between na{\"{\i}}ve and primed iPSCs mentioned in the Figure~\ref{f-def9d660b7b2} and their species of origin can potentially affect the outcomes of the studies conducted and present a significant clinical challenge. While reprogramming efficiency is poor, iPSCs can be extended considerably in culture, resulting in different cell and tissue types \unskip~\citep{649098:15251391}. Unlike ESCs, after the incorporation into pre-implantation embryos, iPSCs can produce cells unlike kidney progenitors and progeny, such as podocytes and tubular epithelial cells Figure~\ref{f-17523ff082a6},\unskip~\citep{649098:15251418}. The great benefit of iPSCs is that they carry the same human genetic history. In essence, they are an ideal tool to study the effect on the pathogenesis of diseases of genetic variants \unskip~\citep{649098:15251400}.


\bgroup
\fixFloatSize{images/7353a562-f5a8-45b1-a578-2b66c2d89d0b-upicture2.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/7353a562-f5a8-45b1-a578-2b66c2d89d0b-upicture2.png}{\includegraphics{images/7353a562-f5a8-45b1-a578-2b66c2d89d0b-upicture2.png}}{}
\makeatother 
\caption{\boldmath {The potential use of renal progenitor cells to kidney regeneration}}
\label{f-def9d660b7b2}
\end{figure}
\egroup
\textbf{The potential application of human pluripotent stem cells}

\textbf{Building a new kidney with human pluripotent stem cells}

\textbf{Organoids}

Organoids contribute to self-definition pluripotent, which they coordinate for the development of small organs and tissues \unskip~\citep{649098:15251408}. Methodology and conceptual advances in organoids have led the researcher to utilize them only for regeneration studies and classical developmental experiments. A renal organoid is, therefore, a basic and miniature version of the kidney that has been developed in vitro. However, early attempts to produce kidney organoids to investigate regeneration resulted in vascular fetal-like kidney tissue\unskip~\citep{649098:15251423}. These barriers can be overcome by using a mouse kidney, a method in which cell dissociation has been proven to integrate with receptors to perform nephron specific function and produce vascularized glomeruli \unskip~\citep{649098:15251426}. The suspension is developed to form chimeric kidney organoids, a mixture of human amniotic fluid SCs and murine embryonic kidney cells \unskip~\citep{649098:15251427}. The ability to produce nephrons from unicellular suspensions marks progress in replacing kidney function by tissue-engineering. A major development in the formation of patient-oriented organoids as a tool for developing the study of human kidney, developing new drugs, studying human kidney development and evaluation of new regeneration approaches that are obtained from the development of human pluripotent SCs. Pluripotent from renal organoid. In fact, from the glomeruli to collecting ducts, human pluripotent SCs spontaneously organized into similar structures to other nephron segments\unskip~\citep{649098:15251421}.

Specifically, contact with iPSCs to various concentrations of Wnt agonists allows authors to obtain SC pluripotent from meta-nephrosis the mesenchymal and urethral buds from the nephron structure. It outlines the most significant steps of embryonic kidney development. Such structures exhibited functional characteristics such that spatial and temporal expression patterns of markers of various segments \textit{of the} nephron\unskip~\citep{649098:15251421} . Nearly at the same time, human ESCs developed ki\textit{dney o}rganoids \unskip~\citep{649098:15251411}. Organoids derived from human pluripotent SCs all contain human fetal kidney material. The renal organization has two main basic functions in relation to regenerative nephrologeny from a scientific point of view morphological evaluation and profile of gene expression assesses the correlation between human fetal kidney cells and associated organ old cells. To define protocols for distinguishing between the specific cell lines of cells that are present within \textit{the or}ganoids \unskip~\citep{649098:15251409}  this technique has contributed to the design and screening of outside cells by patients' specific diseases, as well as for kidney tissue replacement with a biotechnology approach. Organoids, however, are not renal. In Complex management of large body system, which is very important for some people, functional properties cannot be reproduced completely, so this structure is widely considered to be a substitute for the kidney. However, these organoids can also be useful for other medicinal purposes, for example, for studying compounds and drugs.

\textbf{Scaffolds}

Organoids for pluripotential SCs provide interesting information on the ability to self-organization in specific kidney mechanisms that can produce sufficient cells to regenerate kidney if this strategy does not withstand enough cells in order to regenerate the kidney. In this case, it is an interesting hypothesis that biological and artificial structures are "recellularized'' with the right combination of certain forms of kidney cells. These cells can be separated from the tissue/cell of their specific origin by pluripotentiary SC cultivated and extended or \textit{in vitro} differentiation\unskip~\citep{649098:15251409}. Pure silk, 3D polymer arrays, kidney weakening, and extracellular matrix are available for the scaffolding \unskip~\citep{649098:15251401}. This method requires the right configuration of blood vessel structures, regardless of the type of skeleton (this requires proper growth and localization of endothelial cell, smooth muscle, pericytic and interstitial cell) so the blood flow is supplied to a skeleton and then structure then function \unskip~\citep{649098:15251393}. Finally, this newly created structure must communicate with the collecting ducts so that the flow of urine and kidney can perform all of its purposes\unskip~\citep{649098:15251404}. The main objective is to acquire a synthetic kidney that can be translated into the host \unskip~\citep{649098:15251409}.

\textbf{Engineered glomerular filtration barrier and renal tubules}

Glomerular filter barrier (GFB0 is a highly specific structure for blood interaction and screening. The reliability of the GFB is ensured, among other things. By appropriate anatomical and functional organizations, the three main components are glomerular endothelial cells, basement membranes and podocytes. Because many kidney diseases determine loss, the regeneration medicine has to be restored to function GFB and another strategy for the modeling of kidney diseases \unskip~\citep{649098:15251415}. Podocytes are non-proliferating and incapable of cell division and capable post-mitotic cell \unskip~\citep{649098:15251416} It has been demonstrated that podocytes in Bowman capsules can be replaced by ancestral cells, although this regeneration is minimal \unskip~\citep{649098:15251414}. 

Organoids derived from Pluripotent CSs provide interesting information about the ability to regulate themselves in comparable kidney structures. However, this approach may not be important for GFB modeling and the study of renal restoration and dysfunction. In the latest study, iPSC, podocytes were put in the sense of a GFB designed to summarize the properties of human glomerular capillary walls, where mechanical forces resembling pulsed blood flow are provided. Human podocytes derived from iPSCs developed glomerular basement membrane proteins and showed foot processes that confer the typical "local" GFB perm selectivity. The researchers recapitulated the morphological and phenotypic characteristics of primary segmental glomerulosclerosis by inducing damage to podocytes\unskip~\citep{649098:15251412}. This approach can be used to model many other kidney diseases special attention to podocytopathesis (genetic, toxic, infections) cellular and molecular levels of GFB complexity\unskip~\citep{649098:15251415} . A significant number of studies published on the production of devices mimicking the structure of kidney tubules, in tandem with the development if artificial GFB. Some studies used artificial microchips filled with human tubular epithelial cells main lines \unskip~\citep{649098:15251403}.  Bio-artificial kidney tubules were shown, to sum up, some of the most important phenotypic and functional characteristics of the renal tubules as solutes reabsorption, secretionand polarization of cells after exposure to shear microfluidics pressure. The first study introduces new methods, especially with respect to the pipe compartments, to review kidney regeneration. In fact, it makes sense to assume that artificial microdevices (such as acute kidney failure, AKF) summarize and test the efficacy and nephrotoxicity of drugs reliably personally.

\textbf{Understanding kidney regeneration through modeling of renal diseases}

\textbf{Modeling of renal diseases using pluripotent stem cells}

The creation of "diseases in a dish," that is, laboratory models of human renal diseases that can be used to understand the mechanism of diseases, is a major opportunity of human pluripotent disorders Figure~\ref{f-17523ff082a6}. We complement mouse models which are unable to recapitulate fully human genotypes and phenotypes, and the technical and economical production of which is costly, ESC and iPSC have been produced with a gene mutation that is responsible for inherited kidney disease (for example, polycystic dominant kidney diseases and autosomal recessive, Aloport's syndrome). iPSC can be collected from patients having kidney diseases. In iPSC specifically, patients with a mutation that are clearly responsible for this disease, the genome does not need to be edited to review the pathophysiology of the diseases. Several iPSC cell culture is obtained for this purpose, which can be used to equate \textit{in vitro } properties with patient clinical characteristics\unskip~\citep{649098:15251397}.

We are commonly used, for example, for the analysis of cytogenetic processes in autosomal dominant polycystic kidney disease (ADPKD) and the role of polycystin-2 in the pathogenesis of the disease \unskip~\citep{649098:15251396}. Such studies show that in the case of mutated mutants, the cystic phenotype is also lower than 100\% \unskip~\citep{649098:15251398}.  Therefore apportion of these modifications could be species-explicit and these cell communities retain the shift in excitement as well as different variants that could eventually continue as modifiers. Furthermore, the use of iPSC allows for no less than some reproducibility of data obtained from animal models, including mice, to be shown strongly in genotype-phenotype correlation studies after full sequencing population screening. Nevertheless, it is possible to use human iPSCs for drug discovery. Cell culture obtained from iPSCs, being at the same time species-specific and phenotypically diverse, are an ideal tool for studying the effects of new compounds and assessing efficacy, toxicity and pleiotropic effects. The limiting stage tends to be the production of suitable in vitro assays to test the function of interest for all of these purposes. Subsequently, human pluripotentiary SCs can serve as a tool for the identification or validation of new biomarkers for renal disorders (e.g., heart, central nervous system, liver) \unskip~\citep{649098:15251398}. This method would be of particular interest to AKI in the area of nephrology. Nonetheless, the discovery of up/down-regulation of specific genes/molecules in response to AKI would be useful in the early detection of AKI and the preclinical evaluation of drugs/molecules for the treatment of patients, in order to avoid nephrotoxicity and facilitate tubular regeneration. In addition, the analysis of unique phenotypic characteristics in cell cultures obtained from pluripotent SCs carrying mutations in genes responsible for hereditary kidney disease could also be known as biomarkers. For example, cysts in iPSC-produces cell cultures may predict the pathogenicity of ADPKD genetic variants and the growth of the phenotype before the clinical onset, acting as biomarkers of the progression of the disease and potentially of the severity and prognosis of the disease. This may also be helpful for other renal conditions, such as nephrotic syndrome and focal segmental glomerulosclerosis, conceptually\unskip~\citep{649098:15251398}.

\textbf{Applications of Gene editing of Human pluripotent SC}

The different application used for the study are present in the Figure~\ref{f-c0381aa0f636}.


\bgroup
\fixFloatSize{images/cf7cda38-b917-4ab7-9dde-2e97db7c7998-upicture3.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/cf7cda38-b917-4ab7-9dde-2e97db7c7998-upicture3.png}{\includegraphics{images/cf7cda38-b917-4ab7-9dde-2e97db7c7998-upicture3.png}}{}
\makeatother 
\caption{\boldmath {Flow chart regarding the application of gene editing of human pluripotent SC}}
\label{f-c0381aa0f636}
\end{figure}
\egroup
Clarification of gene function cells subject to genome processing must contain any planes isogenic changes, offering comprehensive gene function tests\unskip~\citep{649098:15251397}. Produce kidney organoids from human pluripotent SC that did not work with CRISPR-Cas9 prdocalyxin to research its role in organogenesis of the kidney. Podocalyxin is very important for the differentiation of organoids, with particular focus on the organization of sub-cycle connection, in comparison with wild type organoids 

Human diseases simulation iPSCs derived from patients are commonly used in monogenic modeling disorders since they are easily handled, clonally expanded and distinguished from patients to cells of interest. Applying gene editing enables isogenic controls to be produced by retrieving disease-causing gene mutations, preventing conflict with genetic background and epiphenomena resulting from potential line-to-line variants. In order to better recapitulate disease phenotypes, 3D organoids derived from human iPSC have recently been developed to study cell-cell interaction in a cellular sense imitating human physiology \unskip~\citep{649098:15251413}.  In general, an \textit{in vitro} organoid model for ADPKD used the CSiSPR-Cas9 genome editing method to introduce bi-alleic truncating mutation in PKD1 or PKD2 in human pluripotent SCs \unskip~\citep{649098:15251398}. In addition, patient-derived iPSC can be used not only for modeling personalized diseases but also as a potential platform for drug screening.

Therapy of gene. Ideally, gene editing will lead to new renal disease treatment approaches in the future, either by encouraging the use of genetically modified target mutants for kidney repair and regeneration of non- immunogenic patients own iPSCs or by producing sources of organ replacement therapy combining the human iPSC model genetically modified with 3D organoids. In addition, gene editing may also produce a "universal donor," i.e., human pluripotent SCs with improved immune-compatibility.


\begin{table*}[!htbp]
\caption{\boldmath {Cell therapy approaches in renal failure} }
\label{tw-f1dc8548f994}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.20139999999999997\linewidth-2\tabcolsep}p{\dimexpr.2554\linewidth-2\tabcolsep}p{\dimexpr.16119999999999994\linewidth-2\tabcolsep}p{\dimexpr.22090000000000003\linewidth-2\tabcolsep}p{\dimexpr.1611\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Therapy of cell & Source of cell & Route of application & A requirement for Immuno suppression? & Experimental Studies\\
\tblmidrule 
ES &
  Allogeneic &
  To be found &
  no &
  None to date\\
IPS &
  Autologous &
  To be found &
  no &
  None to date\\
Metanephroi &
  Allogeneic/Xenogeneic &
  Implanted &
  yes &
  None to date\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Tissue and bioengineering approaches}

The tissue and bioengineering methodologies are, all in all, in view of \textit{in vitro } control of the cells of intrigue, furthermore, their relationship with biomaterials, which may be either biodegradable or lasting in nature, to deliver a gadget for implantation or joining into an extracorporeal circuit. Procedures, for example, cell treatment with a solitary separated cell type to supplant a particular metabolic or catabolic capacity are as of now practically speaking, though the biotechnology devices required to manufacture a total working organ for transplantation are still in their outset. Cell-put together, treatments depend with respect to the extension of huge cell populaces that are uniform in action and without pathogen. Current tissue-designing strategies commonly rely upon forebear or changed cell types, despite the fact that the accentuation is probably going to move to an ever-increasing extent to SCs, with focal points to be picked up in adaptable creation without the security concerns connected to changed cell lines. 

Cellular implant removes toxins and delivers therapeutic agents. Potential ways to deal with the treatment of renal disappointment include utilizing cell inserts to evacuate toxins brought about by the ailment state or to convey helpful specialists to the dissemination \unskip~\citep{649098:15251397}. To fuse embeds clinically, techniques to improve have embed immunology, or the utilization of autologous cell sources are required. Epitome is a technique regularly used to bypass the issues related with cell inserts. Exemplification inside a semipermeable, non-degradable polymeric film offers the upside of immune isolating allogeneic or xenogeneic cells and permits a more noteworthy level of command over their goal inside the body while as yet permitting the contact with the organic liquid required to evoke the ideal physiological response \unskip~\citep{649098:15251409}. For model, sodium alginate dots have been utilized to convey hereditarily adjusted microbes communicating the urease catalyst to corrupt, harmful degrees of urea \unskip~\citep{649098:15251401}. Another technique for epitome is to house cells inside empty filaments consolidated into an implantable gadget. For instance, consolidation of erythropoietin (EPO) delivering HepG2 cells known to show oxygen-directed EPO production, \unskip~\citep{649098:15251394} inside the empty filaments of an intravascular embedded device \unskip~\citep{649098:15251393} speaks to a promising option in contrast to the organization of recombinant human EPO\unskip~\citep{649098:15251404}. 

\textbf{Renal assist devices and renal replacement}

Current techniques for complete renal replacement focused on the development of essential renal cells in culture, but combined biomaterial systems for subcutaneous implantation or use in extracorporeal perfusion frameworks. Extended renal cells in culture and seeded them in collagen-covered ducts on polycarbonate films, depending on the cells inborn morphological and hierarchical properties to reconstitute functional nephron units \unskip~\citep{649098:15251407}. Tissue from renal to glomeruli, distal and proxy tubes have been distributed separately \textit{in vitro } and seeded in syngenic hosts for subcutaneous implantation on biodegradable polyglycolic corrosion plates. Signs of vascularization, recognizable nephronic elements including glomeruli proximal tubules, distal tubules, Henle circles, collecting tubules and conducts have also been shown by platform extraction and histological analysis. Nonetheless this component did not seem to be compatible or show association with lower requests. A device consisting of renal cells seeded on a tube-shaped polycarbonate surface connected to a silastic catheter on one side also ended up being evaluated in supply in mice at that stage. The agents showed vascularization and organization of glomeruli and tubular structures \unskip~\citep{649098:15251415}. A fluid obtained from the supply was found to have uric corrosive and creatinine, increasing the possibility that the reconstituted nephronic units might have some functional limit rate. Embryonic renal cells derived from the metanephros of a 56-day cow-like developmental life produced by atomic motion were used as a cell hotspot for a comparative renal cell device\unskip~\citep{649098:15251416}. 

See reports of atomic exchange and remedial cloning methods \unskip~\citep{649098:15251406}. Such devices are subcutaneously implanted in the flank of the comparable creature from which the cloned tissue was deduced. Upon recovery of the product, the store was found to contain limited quantities of fluid that had elevated urea and creatinine, with properties such as cow-like urine. Analysis of the tissue showed vascularization, what's more, the presence of glomeruli and tubular-like structures with no signs of resistant discharge \unskip~\citep{649098:15251416}. Humes et al.'s technique consisted of guiding cell therapy from an extracorporeal loop, taking into account the immunoisolation of a cell device, destroying immunorejection problems and facilitating the use of allogeneic cells. This approach uses hemofiltration as a functioning substitute for glomerular filtration, with metabolic, moreover, secretory elements of proximal tubule cells supplanted by using the Renal Tubular Assistance Gadget (RAD). In the aftermath of trials in creature models and stage I~/ II clinical preliminaries on human patients with ARF, this approach has demonstrated an outstanding guarantee\unskip~\citep{649098:15251403} for a schematic RAD circuit \unskip~\citep{649098:15251392}.

Cell attachment to the empty fiber polysulfone film is progressed by covering with an extracellular lattice, such as collagen type IV. The film is both a medium and an immunological impediment to the cells. In vitro RAD analysis demonstrated separate renal tubule cell potential, including the specific metabolic movement of dynamic vehicle renal cell, and endocrine secretion \unskip~\citep{649098:15251392}. The cell therapy used for real failure is discussed in Table~\ref{tw-f1dc8548f994}. After reciprocal nephrectomy, RADs containing either porcine or human cells on uremic canines were evaluated in ex vivo creature testing. In RAD-treated animals, improvements in various physiological parameters were seen contrasting with acellular RAD controls\$. In addition, RAD treatment appeared in canine and porcine ARF models with septic stun to change plasma cytokine levels, enhance cardiovascular efficiency, and increase survival \unskip~\citep{649098:15251399}. A preliminary clinical stage I~/ II Food and Drug Administration in 10 profoundly ill patients with ARF and MOF approving nonstop venovenous hemofiltration (CVVH) used RADs seeded with human kidney cells isolated from cadaveric kidneys that are not suitable for transplantation due to anatomical or fibrotic defects \unskip~\citep{649098:15251425}.

The findings of this review showed that RAD therapy can be transmitted safely for up to 24 h in this profoundly sick patient population under examination convention rules and that the gadget is rational, durable and useful through therapy\unskip~\citep{649098:15251425}. In a preliminary randomized, monitored, open-name stage II, involving 58 AKI patients at 12 clinical destinations, RAD care for up to 72 h advanced a measurably significant survival advantage (33\% death at day 28) over typical CVVH (61\% death at day 28)\unskip~\citep{649098:15251402} . Due to the difficulties found with the generation and dispersion of RAD devices, a subsequent stage IIb concentrate on testing a company assembly method was not done. A notable barrier in the far-reaching receipt of renal cell treatment is the lack of a cryopreserve system to allow transportation, processing and restorative use in care facilities \unskip~\citep{649098:15251428} .  Building on the accomplishment of the RAD, Humes, et al. created the Bioartificial Renal Epithelial Cell System (BRECS), a gadget that acts as a joined bioreactor, cryostorage gadget, and cell treatment conveyance system. Quickly, permeable carbon plates coated with niobium were used as cell platforms within the BRECS, and culture media were perfused through and around the permeable plates. An expanded proliferation method late produced, taking into account the enhancement of kidney ancestor cells from critical confines to fill in as an effective, helpful cell hotspot for BRECS seeding. Using the characterized extended proliferation technique resulted in an increase of up to 8 cell yield orders over memorable generic engendering techniques. What's more, in vitro glucose levels, the use of oxygen, lactate age, and glutathione degradation indicate support for more than 1 3 108 cells in each BRECS over 5 months in culture\unskip~\citep{649098:15251429}. Ex vivo's huge creature claims that using normal hemofiltration-related BRECS is a safe way to treat both ARF and ESRD \unskip~\citep{649098:15251413}.
    
\section{Conclusion}
Knowing kidney regeneration mechanisms of molecular and cellular processes is critical for developing new therapeutic policies for reversing and/or increasing renal harm to order to avoid permanent nephronic loss and CKD, this should preferably support efforts to improve therapeutically regeneration the kidney. The implementation of a miniaturized organ on a chip system that combines biological and engineering techniques is another way to restore kidney function.
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
